scholarly journals Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis

2018 ◽  
Vol 76 (9) ◽  
pp. 588-591 ◽  
Author(s):  
Luciana Prats Branco ◽  
Tarso Adoni ◽  
Samira Luisa Apostolos-Pereira ◽  
Joseph Bruno Bidin Brooks ◽  
Eber Castro Correa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Immunosorbent Assay ◽  
Treatment Options ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Antibodies ◽  
John Cunningham Virus ◽  
Blood Tests ◽  
Serological Profile

ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.

scholarly journals Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities

2019 ◽  
Vol 116 (44) ◽  
pp. 22246-22251 ◽  
Author(s):  
Salahaldin A. Tahir ◽  
Jianjun Gao ◽  
Yuji Miura ◽  
Jorge Blando ◽  
Rebecca S. S. Tidwell ◽  
...  
Keyword(s):  
Adverse Events ◽  
Cancer Patients ◽  
Immunosorbent Assay ◽  
Immune Checkpoint ◽  
Additional Patient ◽  
Enzyme Linked Immunosorbent Assay ◽  
Plasma Samples ◽  
Serological Analysis ◽  
Autoimmune Antibodies ◽  
Expression Libraries

Immune checkpoint (IC) therapy provides substantial benefits to cancer patients but can also cause distinctive toxicities termed immune-related adverse events (irAEs). Biomarkers to predict toxicities will be necessary to improve management of patients receiving IC therapy. We relied on serological analysis of recombinant cDNA expression libraries to evaluate plasma samples from patients treated with IC therapy and identified autoantibodies, both in pretreatment and on-treatment samples prior to the development of irAEs, which correlate with the development of immune-related hypophysitis (anti-GNAL and anti-ITM2B autoantibodies) and pneumonitis (anti-CD74 autoantibody). We developed an enzyme-linked immunosorbent assay and tested additional patient samples to confirm our initial findings. Collectively, our data suggest that autoantibodies may correlate with irAEs related to IC therapy, and specific autoantibodies may be detected early for the management of irAEs.

Severe haematological complications during treatment with natalizumab

2012 ◽  
Vol 18 (11) ◽  
pp. 1644-1646 ◽  
Author(s):  
L Midaglia ◽  
M Rodriguez Ruiz ◽  
D Muñoz-García
Keyword(s):  
Multiple Sclerosis ◽  
Adverse Events ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Immune Thrombocytopenic Purpura ◽  
Safety Profile ◽  
Temporal Relationship ◽  
Careful Monitoring ◽  
Thrombocytopenic Purpura ◽  
Immune Mediated ◽  
Immunosuppressant Treatment

The safety profile of natalizumab has been widely discussed due to several cases of progressive multifocal leukoencephalopathy, reported worldwide. Since the launch of natalizumab, 32 patients have been treated at our centre. In this context, we describe two cases (6.25%), one of immune-mediated acute haemolytic anaemia (IAHA) and another of immune thrombocytopenic purpura during treatment with natalizumab. The temporal relationship between drug administration and the nature of the haematological complications, confirmed with the serological findings in the case of the IAHA, suggests that natalizumab is the most probable cause for these adverse events. Although very uncommon, the haematological complications are severe enough to justify a close and careful monitoring for all patients with multiple sclerosis treated with an immunosuppressant treatment.

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis

2014 ◽  
Vol 20 (13) ◽  
pp. 1699-1703 ◽  
Author(s):  
Elodie Nerrant ◽  
Céline Salsac ◽  
Mahmoud Charif ◽  
Xavier Ayrignac ◽  
Clarisse Carra-Dalliere ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Potassium Channel ◽  
Immunosorbent Assay ◽  
Neurological Diseases ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Lower Prevalence ◽  
Immunofluorescence Analysis ◽  
Specific Staining ◽  
Inward Rectifying Potassium Channel

Background: auto-antibodies against the potassium channel inward rectifying potassium channel 4.1 (Kir4.1) have previously been identified in 46% of patients with multiple sclerosis (MS). Objectives: to confirm these findings. Methods: we evaluated the presence of anti-Kir4.1 antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence in 268 MS patients, 46 patients with other neurological diseases (OND) and 45 healthy controls. Results: anti-Kir4.1 antibodies were found in 7.5% of MS patients, 4.3% of OND patients and 4.4% of healthy controls. Immunofluorescence analysis did not identify any specific staining. Conclusions: we confirmed the presence of anti-Kir4.1 antibodies in MS patients, but at a much lower prevalence than previously reported.

Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use

2009 ◽  
Vol 15 (4_suppl) ◽  
pp. 16-25 ◽  
Author(s):  
Carlo Tornatore ◽  
David B Clifford
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multifocal Leukoencephalopathy ◽  
Clinical Outcomes ◽  
Treatment Options ◽  
Current Treatment ◽  
Recent History ◽  
Clinical Guidance ◽  
Disease States ◽  
History Of

Natalizumab therapy for patients with multiple sclerosis (MS) has been associated with both improved clinical outcomes and an increased incidence of progressive multifocal leukoencephalopathy (PML). We provide details of the etiology and recent history of PML as associated with immunosuppressive disease states, including MS. Furthermore, it offers clinical guidance on differentiating PML from a MS relapse and a review of the current treatment options for patients suspected of having developed the complication.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy

2015 ◽  
Vol 21 (12) ◽  
pp. 1600-1603 ◽  
Author(s):  
Anke Vennegoor ◽  
Johannis A van Rossum ◽  
Chris H Polman ◽  
Mike P Wattjes ◽  
Joep Killestein
Keyword(s):  
Multiple Sclerosis ◽  
Risk Factor ◽  
Progressive Multifocal Leukoencephalopathy ◽  
High Serum ◽  
Saturation Level ◽  
Antibody Index ◽  
John Cunningham Virus ◽  
Multiple Sclerosis Patients

The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested that an increase in serum anti-JCV antibody index precedes the development of PML. We here describe extensive longitudinal serum anti-JCV antibody indexes of four MS patients who developed PML. Anti-JCV antibodies were measured using the STRATIFY JCV™DxSelect™ test. All four patients had rather stable high anti-JCV antibody indexes in all samples obtained before developing PML. Possibly caused by reaching the saturation level of the assay, no increase in anti-JCV antibody indexes was seen just before the diagnosis of PML. This study confirms that high serum anti-JCV antibody indexes precede natalizumab-associated PML.

Sign in / Sign up

Export Citation Format

Share Document